Pharmaceuticals
Piecing Together a Portfolio of Lovable Losers Could Be Tough This December
The early potential candidates for the next Tax Loss Selling Recovery Portfolio are few and far between.
GlaxoSmithKline Needs More Positive Developments Before Investing
Here's what Jim Cramer expects to hear from GSK at this week's investor meeting.
2 Biotech Stocks That Make for Good Covered Call Plays
Clearside Biomedical and Omeros Corp. both have promising products that should win regulatory approval in the coming months.
Jim Cramer: I Warned You That Betting Against Science Is a Mug's Game
And I was right, and the cynics were wrong. Here's why that matters more than ever now.
Speculative Mind Medicine Could Double or Triple From Here
My recommendation is not for the shy, timid, or new trader.
The Johnson & Johnson Charts Are Healthy Enough for Further Gains
Here's where traders could probe the long side of JNJ.
Wait a Few Days to Trade Vertex So You Don't Get Your Face Ripped Off
While it's tempting to take on a long-side trade here, I don't see a good reason.
AstraZeneca Is Moving the Needle
This drugmaker is making a historic upside breakout. Let's check the charts.
Why Drugmaker Perrigo Could Surprise on the Upside
PRGO traded up sharply Thursday -- and may not be done.
Following Up on Our Regeneron Recommendation
Here's what traders should consider doing now.